A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients
Clinical trial NCT00001669 · COMPLETED
Trial details
- NCT number
- NCT00001669
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 1997-07-01
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.